Jazz Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference

Hamilton, Bermuda – 7 June 2018 – In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ) whose Secured Loan Notes are

listed on the BSX announces it will Present at the Goldman Sachs Global Healthcare Conference. The full filing stated:

DUBLIN, June 6, 2018 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Goldman

Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA.

Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update at the conference on

Wednesday, June 13, 2018 at 9:20 a.m. PDT
/ 5:20 p.m. IST.

A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at

http://www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads

that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company’s website at

http://www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and

commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates with a focus in

the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase

Erwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeos® (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase® and

Defitelio® (defibrotide) in countries outside the U.S. For country-specific product information, please visit  http://www.jazzpharmaceuticals.com/products.

For more information, please visit  http://www.jazzpharmaceuticals.com and follow us on Twitter at @JazzPharma.

 
Jazz Pharmaceuticals Contacts:

Investors:
Kathee Littrell
Vice President, Investor Relations Ireland, +353 1 634 7887
U.S., +1 650 496 2717
 


Media:
Jacqueline Kirby
Vice President, Corporate Affairs & Government Relations Ireland, +353 1 697 2141
U.S., +1 215 867 4910